HC Wainwright Brokers Boost Earnings Estimates for NextCure

NextCure, Inc. (NASDAQ:NXTC) – Investment analysts at HC Wainwright boosted their Q3 2026 earnings per share estimates for NextCure in a research note issued on Wednesday, August 12th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.90) per share for the quarter, up from their previous estimate of ($2.00). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for NextCure’s current full-year earnings is ($7.99) per share. HC Wainwright also issued estimates for NextCure’s Q4 2026 earnings at ($0.79) EPS, FY2027 earnings at ($1.38) EPS, FY2028 earnings at ($1.22) EPS, FY2029 earnings at ($0.75) EPS and FY2030 earnings at $0.12 EPS.

NXTC has been the subject of several other reports. Wall Street Zen downgraded NextCure from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings raised shares of NextCure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. Finally, Zacks Research upgraded shares of NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, NextCure has an average rating of “Hold” and a consensus target price of $19.00.

NextCure Price Performance

NXTC opened at $8.28 on Friday. The business has a 50 day moving average price of $3.69 and a two-hundred day moving average price of $8.24. NextCure has a 1-year low of $1.55 and a 1-year high of $15.74. The company has a market capitalization of $29.89 million, a price-to-earnings ratio of -0.95 and a beta of 1.27.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by ($0.85).

Insider Buying and Selling at NextCure

In related news, major shareholder Adar1 Capital Management, Llc bought 292,850 shares of the business’s stock in a transaction on Thursday, July 30th. The shares were purchased at an average price of $4.93 per share, with a total value of $1,443,750.50. Following the completion of the purchase, the insider owned 686,116 shares of the company’s stock, valued at $3,382,551.88. This represents a 74.47% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders acquired 346,761 shares of company stock valued at $1,710,807. Corporate insiders own 11.90% of the company’s stock.

Hedge Funds Weigh In On NextCure

Several institutional investors and hedge funds have recently modified their holdings of NXTC. Marshall Wace LLP bought a new position in NextCure in the fourth quarter valued at $160,000. Millennium Management LLC acquired a new position in shares of NextCure in the fourth quarter valued at about $185,000. Geode Capital Management LLC raised its position in shares of NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after buying an additional 3,636 shares in the last quarter. Cable Car Capital LP lifted its stake in NextCure by 13.1% during the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after purchasing an additional 88,040 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in NextCure by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after buying an additional 5,300 shares in the last quarter. 42.65% of the stock is currently owned by institutional investors and hedge funds.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.